keyword
MENU ▼
Read by QxMD icon Read
search

troponin I heart failure

keyword
https://www.readbyqxmd.com/read/29147972/plasma-osteopontin-levels-in-patients-with-dilated-and-hypertrophic-cardiomyopathy
#1
J Podzimkova, T Palecek, P Kuchynka, J Marek, B A Danek, M Jachymova, M Kalousova, T Zima, A Linhart
BACKGROUND: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies...
November 16, 2017: Herz
https://www.readbyqxmd.com/read/29143665/cardiopulmonary-and-inflammatory-biomarkers-in-heartworm-disease
#2
REVIEW
Elena Carretón, Rodrigo Morchón, José Alberto Montoya-Alonso
In heartworm disease, several biomarkers of cardiopulmonary injury and inflammatory activity have been studied during the recent years. D-dimer is a fibrin degradation product present after a clot is degraded, which has been reported to provide support for the diagnosis of pulmonary thromboembolism in heartworm disease. Furthermore, concentrations increment with increased disease severity and during the adulticide treatment. This increase in concentration has proved to be valuable. Cardiac biomarkers troponin I, myoglobin and NT-proBNP demonstrated presence of myocardial injury and heart failure, especially in chronic infections, which in some cases, slightly improve after the adulticide treatment...
November 9, 2017: Parasites & Vectors
https://www.readbyqxmd.com/read/29066610/high-sensitivity-cardiac-troponin-i-and-risk-of-cardiovascular-disease-in-an-australian-population-based-cohort
#3
Kun Zhu, Matthew Knuiman, Mark Divitini, Kevin Murray, Ee Mun Lim, Andrew St John, John P Walsh, Joseph Hung
OBJECTIVE: High-sensitivity cardiac troponin I (hs-cTnI) is an emerging biomarker for cardiovascular risk. We examined hs-cTnI as a predictor of mortality and cardiovascular outcomes in an Australian population-based cohort and evaluated if a sex difference exists. METHODS: Serum hs-cTnI was measured in the Busselton Health Study 1994/1995 Cohort (n=3939). Outcome measures were total and cardiovascular mortality, cardiovascular disease (CVD) and coronary heart disease (CHD) events, heart failure and stroke...
October 24, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29066436/interleukin-6-and-the-risk-of-adverse-outcomes-in-patients-after-an-acute-coronary-syndrome-observations-from-the-solid-timi-52-stabilization-of-plaque-using-darapladib-thrombolysis-in-myocardial-infarction-52-trial
#4
Christina L Fanola, David A Morrow, Christopher P Cannon, Petr Jarolim, Mary Ann Lukas, Christoph Bode, Judith S Hochman, Erica L Goodrich, Eugene Braunwald, Michelle L O'Donoghue
BACKGROUND: Interleukin-6 (IL-6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndrome (ACS). We aimed to evaluate the prognostic implications of IL-6 post-ACS. METHODS AND RESULTS: IL-6 concentration was assessed at baseline in 4939 subjects in SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients ≤30 days from ACS. Patients were followed for a median of 2...
October 24, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29045610/high-sensitivity-cardiac-troponin-i-and-risk-of-heart-failure-in-patients-with-suspected-acute-coronary-syndrome-a-cohort-study
#5
Dominik Stelzle, Anoop S V Shah, Atul Anand, Fiona E Strachan, Andrew R Chapman, Martin A Denvir, Nicholas L Mills, David A McAllister
Aims: Heart failure may occur following acute myocardial infarction, but with the use of high-sensitivity cardiac troponin assays we increasingly diagnose patients with minor myocardial injury. Whether troponin concentrations remain a useful predictor of heart failure in patients with acute coronary syndrome is uncertain. Methods and results: We identified all consecutive patients (n = 4748) with suspected acute coronary syndrome (61 ± 16 years, 57% male) presenting to three secondary and tertiary care hospitals...
July 19, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/29044915/pre-discharge-and-early-post-discharge-troponin-elevation-among-patients-hospitalized-for-heart-failure-with-reduced-ejection-fraction-findings-from-the-astronaut-trial
#6
Stephen J Greene, Javed Butler, Gregg C Fonarow, Haris P Subacius, Andrew P Ambrosy, Muthiah Vaduganathan, Marco Triggiani, Scott D Solomon, Eldrin F Lewis, Aldo P Maggioni, Michael Böhm, Ovidiu Chioncel, Savina Nodari, Michele Senni, Faiez Zannad, Mihai Gheorghiade
AIMS: Troponin levels are commonly elevated among patients hospitalized for heart failure (HF), but the prevalence and prognostic significance of early post-discharge troponin elevation are unclear. This study sought to describe the frequency and prognostic value of pre-discharge and post-discharge troponin elevation, including persistent troponin elevation from the inpatient to outpatient settings. METHODS AND RESULTS: The ASTRONAUT trial (NCT00894387; http://www...
October 17, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29025373/the-prognostic-value-of-high-sensitive-cardiac-troponin-i-in-patients-receiving-cardiac-resynchronisation-therapy
#7
Michal Kerekanič, Marek Hudák, Silvia Mišíková, Erika Komanová, Alexander Bohó, Ján Kyselovič, Branislav Stančák
BACKGROUND: Cardiac troponin I (cTnI) is a valuable prognostic biomarker in patients with chronic heart failure (CHF). However, the prognostic importance of cTnI in patients who received cardiac resynchronisation therapy (CRT) remains unknown. The aim of this prospective study was to determine the prognostic value of high-sensitive cTnI (hs-cTnI) in CHF patients receiving CRT. METHODS: We performed measurements of baseline hs-cTnI levels in CRT patients with ischaemic as well as nonischaemic aetiology of CHF, and we investigated their possible association with response to CRT and survival of patients...
October 12, 2017: Acta Cardiologica
https://www.readbyqxmd.com/read/28984473/the-continuing-evolution-of-cardiac-troponin-i-biomarker-analysis-from-protein-to-proteoform
#8
Daniel Soetkamp, Koen Raedschelders, Mitra Mastali, Kimia Sobhani, C Noel Bairey Merz, Jennifer Van Eyk
The troponin complex consists of three proteins that fundamentally couple excitation with contraction. Circulating cardiac-specific Troponin I (cTnI) serves as diagnostic biomarker tools for risk stratification of acute coronary syndromes and acute myocardial infarction (MI). Within the heart, cTnI oscillates between inactive and active conformations to either block or disinhibit actinomyosin formation. This molecular mechanism is fine-tuned through extensive protein modifications whose profiles are maladaptively altered with co-morbidities including hypertrophic cardiomyopathy, diabetes, and heart failure...
November 2017: Expert Review of Proteomics
https://www.readbyqxmd.com/read/28983818/in-search-of-an-efficient-strategy-to-monitor-disease-status-of-chronic-heart-failure-outpatients-added-value-of-blood-biomarkers-to-clinical-assessment
#9
N van Boven, K M Akkerhuis, S S Anroedh, L C Battes, K Caliskan, W Yassi, O C Manintveld, J H Cornel, A A Constantinescu, H Boersma, V A Umans, I Kardys
INTRODUCTION: Blood biomarkers have the potential to monitor the severity of chronic heart failure (CHF). Studies correlating repeated measurements of blood biomarkers with repeatedly assessed New York Heart Association (NYHA) class over a prolonged follow-up period, and concomitantly investigating their associations with clinical endpoints, have not yet been performed. METHODS: Between 2011-2013, 263 CHF patients were included. At inclusion and subsequently every 3 months, we measured N‑terminal pro-B-type natriuretic (NT-proBNP), high-sensitivity troponin T (Hs-TnT) and C‑reactive protein (CRP), and assessed NYHA class...
November 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28952056/pathophysiology-of-acute-heart-failure-syndrome-a-knowledge-gap
#10
REVIEW
Hani N Sabbah
Although much remains unknown regarding the pathophysiology of acute heart failure (AHF), precipitating events are thought to involve a complex set of interactions between the heart, kidneys, and peripheral vasculature. In addition to these interactions, which are considered the primary abnormalities in patients with AHF, several other organ systems may also be affected and contribute to disease progression. Currently available scientific literature suggests that the natural history and pathophysiology of AHF consists of two phases: (1) an "initiation phase" involving a series of triggering events, and (2) an "amplification phase," in which multiple mechanisms contribute to worsening HF and exacerbate end-organ damage...
November 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28912910/prognostic-significance-of-elevated-cardiac-troponin-in-acute-gastrointestinal-bleeding
#11
Umair Iqbal, Osama Siddique, Ayesha Jameel, Hafsa Anwar, Ahmad Chaudhary
BACKGROUND: Acute gastrointestinal bleeding (AGIB) is responsible for over 140,000 hospitalizations annually. Cardiovascular-related deaths account for 30% of the patients surviving the initial episode of AGIB. The purpose of this study was to identify the impact of elevated troponin on short-term mortality and length of stay (LOS) of these patients. METHODS: From July 2013 to July 2016, 290 patients admitted with a diagnosis of AGIB and who had cardiac troponin I measured within 24 h of presentation were retrospectively reviewed...
August 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28906388/retrospective-cause-analysis-of-troponin-i-elevation-in-non-cad-patients-special-emphasis-on-sepsis
#12
Chien-Wen Yang, Huijun Li, Lisa Thomas, Manuel Ramos, Po-Hong Liu, Thomas Roe, Ravinder Valadri, Michael C Kiel, Vincent Yi-Fong Su, Qi Shi
BACKGROUND: Troponin I is one of the most commonly tested biochemical markers in the emergency room (ER) and in the hospital setting. Besides coronary artery disease (CAD), demand ischemia with underlying tachycardia, anemia, hypertensive emergency, congestive heart failure, kidney disease, sepsis, and pulmonary embolism have also been reported to cause troponin I elevations. Few reports have excluded patients with CAD, and no study has summarized the proportion of these factors relative to an increased troponin I level...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28899987/heart-failure-related-hyperphosphorylation-in-the-cardiac-troponin-i-c-terminus-has-divergent-effects-on-cardiac-function-in-vivo
#13
Yuejin Li, Guangshuo Zhu, Nazareno Paolocci, Pingbo Zhang, Cyrus Takahashi, Nazli Okumus, Amir Heravi, Gizem Keceli, Genaro Ramirez-Correa, David A Kass, Anne M Murphy
BACKGROUND: In human heart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated, and in vitro studies suggest that it enhances myofilament calcium sensitivity and alters calpain-mediated cTnI proteolysis. However, how its hyperphosphorylation affects cardiac function in vivo remains unknown. METHODS AND RESULTS: To address the question, 2 transgenic mouse models were generated: a phospho-mimetic cTnIS200D and a phospho-silenced cTnIS200A, each driven by the cardiomyocyte-specific α-myosin heavy chain promoter...
September 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28890872/cardiac-troponin-and-outcome-in-decompensated-heart-failure-with-preserved-ejection-fraction
#14
Mohammad Thawabi, Amer Hawatmeh, Sarah Studyvin, Habib Habib, Fayez Shamoon, Marc Cohen
BACKGROUND: Cardiac troponin (cTn) has been established as an effective prognostic marker in acute heart failure (HF) with predominantly reduced ejection fraction. However, it's prognostic value in heart failure with preserved ejection fraction (HFpEF) is unclear. The aim of this study is to describe the prognostic role of troponin I in patients hospitalized for HFpEF decompensation. METHODS: We included 363 consecutive patients admitted for HFpEF decompensation that was not associated with acute coronary syndrome (ACS)...
August 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/28884991/acute-cardiac-disease-in-a-patient-with-hyper-ige-syndrome
#15
A Castilano, H Watti, A Abdulbaki, K Modi, J A Bocchini, S L Bahna
We describe the case of a 24-year-old male with hyper-IgE syndrome (HIES) which was diagnosed at 4 years of age and died from a very rare cardiac complication. He had typical clinical and laboratory manifestations of HIES, including total serum IgE as high as > 100,000 IU/mL. Stem cell transplantation was not available. During the 20-year follow-up, he suffered numerous various infections of the skin and deep organs, partial lung resection, as well as multiple bone fractures. At age 24, he developed acute decompensated heart failure associated with elevated serum troponin I and brain natriuretic protein...
September 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28877565/prognostic-significance-of-troponin-elevation-for-long-term-mortality-after-ischemic-stroke
#16
Sung-Ho Ahn, Ji-Sung Lee, Young-Hak Kim, Bum Joon Kim, Yeon-Jung Kim, Dong-Wha Kang, Jong S Kim, Sun U Kwon
BACKGROUND AND PURPOSE: Troponin, a marker of myocardial injury, frequently increases and is related with poor outcome in ischemic stroke patients. However, the long-term outcome of this elevation remains uncertain. We, therefore, investigated the prognostic significance of troponin elevation for long-term mortality, and explored factors affecting troponin elevation after ischemic stroke. METHODS: We retrospectively analyzed the medical data of stroke patients who were admitted within 24 hours of symptom onset and underwent a serum cardiac troponin I test at admission during a five-year period...
September 2017: Journal of Stroke
https://www.readbyqxmd.com/read/28862043/study-of-the-safety-of-extracorporeal-cardiac-shock-wave-therapy-observation-of-the-ultrastructures-in-myocardial-cells-by-transmission-electron-microscopy
#17
Bing Liu, Yunhe Zhang, Na Jia, Ming Lan, Ling Du, Dachun Zhao, Qing He
Extracorporeal cardiac shock wave therapy (CSWT) has been used to treat patients with severe coronary heart disease and cardiac failure with good results; however, the safety of this treatment is still controversial. Its safety in clinical setting and on microstructures has been confirmed, but the influence of shock wave on the ultrastructures of myocardial cells is not clear. In this study, 12 Sprague-Dawley rats were randomly divided into control (NC) and CSWT therapy (NC+SW) groups. The heart rate, blood pressure, serum troponin I (TNI), and cardiac ultrasound were evaluated, and the myocardial inflammatory responses and fibrosis changes were compared...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28854816/carvedilol-inhibits-matrix-metalloproteinase-2-activation-in-experimental-autoimmune-myocarditis-possibilities-of-cardioprotective-application
#18
Monika Skrzypiec-Spring, Katarzyna Haczkiewicz, Agnieszka Sapa, Tomasz Piasecki, Joanna Kwiatkowska, Ireneusz Ceremuga, Mieczyslaw Wozniak, Wieslawa Biczysko, Christopher Kobierzycki, Piotr Dziegiel, Marzenna Podhorska-Okolow, Adam Szelag
AIMS: Acute myocarditis is a potentially lethal inflammatory heart disease that frequently precedes the development of dilated cardiomyopathy and subsequent heart failure. At present, there is no effective standardized therapy for acute myocarditis, besides the optimal care of heart failure and arrhythmias in accordance with evidence-based guidelines and specific etiology-driven therapy for infectious myocarditis. Carvedilol has been shown to be cardioprotective by reducing cardiac pro-inflammatory cytokines present in oxidative stress in certain heart diseases...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28830541/cardioprotective-effect-of-platycodon-grandiflorum-in-patients-with-early-breast-cancer-receiving-anthracycline-based-chemotherapy-study-protocol-for-a-randomized-controlled-trial
#19
Wei Hao, Sheng Liu, Yuenong Qin, Chenping Sun, Liying Chen, Chunyu Wu, Yijia Bao
BACKGROUND: Anthracyclines, alone or in combination with other drugs, are among the most effective chemotherapeutic agents to treat breast cancer both in the adjuvant and neoadjuvant setting. Unfortunately, anthracycline-associated dose-dependent cardiotoxicity is a limiting factor in clinical use. Extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity. However, most cardioprotective agents have shown little effect in clinical trials...
August 22, 2017: Trials
https://www.readbyqxmd.com/read/28829419/in-vitro-differentiation-of-human-mesenchymal-stem-cells-into-functional-cardiomyocyte-like-cells
#20
Peter Szaraz, Yarden S Gratch, Farwah Iqbal, Clifford L Librach
Myocardial infarction and the subsequent ischemic cascade result in the extensive loss of cardiomyocytes, leading to congestive heart failure, the leading cause of mortality worldwide. Mesenchymal stem cells (MSCs) are a promising option for cell-based therapies to replace current, invasive techniques. MSCs can differentiate into mesenchymal lineages, including cardiac cell types, but complete differentiation into functional cells has not yet been achieved. Previous methods of differentiation were based on pharmacological agents or growth factors...
August 9, 2017: Journal of Visualized Experiments: JoVE
keyword
keyword
62109
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"